889939-25-7

Basic information

• Product Name: 4-BROMO-1-(PHENYLSULFONYL)-1H-PYRROLO[2,3-B]PYRIDINE
• Synonyms: 4-BROMO-1-(PHENYLSULFONYL)-1H-PYRROLO[2,3-B]PYRIDINE;4-BROMO-1-BENZENESULFONYL-7-AZAINDOLE;1H-Pyrrolo[2,3-b]pyridine, 4-bromo-1-(phenylsulfonyl)-;1-Benzenesulfonyl-4-bromo-7-azaindole;4-Bromo-1-benzenesulfonyl...;1-(benzenesulfonyl)-4-broMo-1H-pyrrolo[2,3-b]pyridine;1-(Phenylsulphonyl)-4-broMo-7-azaindole;1-(phenylsulfonyl)-4-bromo-7-azaindole
• CAS NO: 889939-25-7
• Molecular Formula: C₁₃H₉BrN₂O₂S
• Molecular Weight: 337.19
• EINECS: 200-589-5
• Mol File: 889939-25-7.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 511.4 °C at 760 mmHg
• Flash Point: 263.1 °C
• Appearance: /
• Density: 1.64±0.1 g/cm3 (20 ºC 760 Torr)
• Vapor Pressure: 1.42E-10mmHg at 25°C
• Refractive Index: 1.699
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 4-BROMO-1-(PHENYLSULFONYL)-1H-PYRROLO[2,3-B]PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-1-(PHENYLSULFONYL)-1H-PYRROLO[2,3-B]PYRIDINE(889939-25-7)
• EPA Substance Registry System: 4-BROMO-1-(PHENYLSULFONYL)-1H-PYRROLO[2,3-B]PYRIDINE(889939-25-7)

Safety Data

• Hazardous Substances Data: 889939-25-7(Hazardous Substances Data)

Usage

General Description

4-Bromo-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine is a chemical compound that is commonly used in pharmaceutical research and development. It belongs to the pyrrolopyridine class of compounds and is known for its potential as a kinase inhibitor. 4-BROMO-1-(PHENYLSULFONYL)-1H-PYRROLO[2,3-B]PYRIDINE has been studied for its potential use in treating various medical conditions, including cancer and inflammatory diseases. Its unique structure and properties make it a valuable tool in the development of new medications and therapies. Additionally, 4-Bromo-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine has been the subject of various studies to understand its biological activity and potential therapeutic applications.

InChI:InChI=1/C13H9BrN2O2S/c14-12-6-8-15-13-11(12)7-9-16(13)19(17,18)10-4-2-1-3-5-10/h1-9H

Upstream product

• 98-09-9 benzenesulfonyl chloride 
• 55052-24-9 1H-Pyrrolo[2,3-b]pyridine-7-oxide 
• 271-63-6 7-Azaindole 

Downstream Products

• 1198438-14-0 1-(phenylsulfonyl)-6-[1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-indazol-4-amine 
• 1261080-57-2 (S)-N-(1-amino-3-(2,4-dichlorophenyl)propan-2-yl)-2-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiazole-5-carboxamide 
• 1261080-70-9 ethyl 2-(1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine-4-yl)thiazole-5-carboxylate 
• 1261080-71-0 2-(1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)thiazole-5-carboxylic acid 
• 1261080-72-1 (S)-N-(1-azido-3-(2,4-dichlorophenyl)propan-2-yl)-2-(1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)thiazole-5-carboxamide 
• 1261080-73-2 (S)-N-(1-azido-3-(2,4-dichlorophenyl)propan-2-yl)-2-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiazole-5-carboxamide 
• 1014612-92-0 1-(phenylsulfonyl)-4-[4-(1-pyrrolidinylsulfonyl)phenyl]-1H-pyrrolo[2,3-b]pyridine 

Relevant articles and documents

The condensed heterocyclic compound such as Bruton kinase inhibitors (by machine translation)

The invention relates to a fused heterocycle derivative and an application, which has a structure shown in a formula 1). The compound with the structure shown in the formula 1) has good inhibition effect to Bruton kinases activity, and median inhibitory concentration is lower than 10mol.L generally.

New thiazole carboxamides as potent inhibitors of Akt kinases

A new series of 2-substituted thiazole carboxamides were identified as potent pan inhibitors against all three isoforms of Akt (Akt1, Akt2 and Akt3) by systematic optimization of weak screening hit N-(1-amino-3-phenylpropan-2-yl)- 2-phenylthiazole-5-carboxamide (1). One of the most potent compounds, 5m, inhibited the kinase activities of Akt1, Akt2 and Akt3 with IC50 values of 25, 196 and 24 nM, respectively. The compound also potently inhibited the phosphorylation of downstream MDM2 and GSK3β proteins, and displayed strongly antiproliferative activity in prostate cancer cells. The inhibitors might serve as lead compounds for further development of novel effective anticancer agents.